Clinical trial · Observational
Volatile Organic Compounds (VOCs) Profile in Colorectal Cancer Patients and Healthy Controls.
Volatile Organic Compounds (VOCs) Could Discriminate Patients With Colorectal Cancer From Healthy Controls.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Volatile organic compounds (VOCs) are low molecular weight (\<1 kDa) compounds which represent the final products of cell metabolism. Their composition can be affected by several factors including diet, hormones, environment and the presence of diseases, in particular, cancer. Colorectal cancer (CRC) is one of the commonest tumours and is an important cause of cancer-related mortality. The expression of VOCs in breath that are linked to a patient's disease state could offers a powerful, non-invasive approach to identifying CRC patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colon Polyp | — | UNRESOLVED | — |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Breath sampling | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Colorectal cancer patients
- description
- Patients with histologically proven Colorectal cancer detected during the colonoscopy
- interventionNames
- Diagnostic Test: Breath sampling
- label
- healthy controls
- description
- Patients with no sign of any colorectal disease who are submitted to colonoscopy
- interventionNames
- Diagnostic Test: Breath sampling
Primary outcomes (1)
- measure
- Test Sensitivity and specificity for colorectal cancer
- timeFrame
- 30 days
- description
- A specificity of 80% and a sensitivity of 90% will be considered reliable
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 95 Years
Show eligibility criteria text
Inclusion Criteria: * Age between 18 and 95 * Histologically proven colorectal cancer * Patient with single or multiple polyps of the colon * Healthy subjects with negative colonoscopy * Patients already sampled and operated for colorectal cancer with no sign of recurrence * Written informed consent Exclusion Criteria: * Pregnancy * Inflammatory bowel disease * Synchronous cancers * Liver and/or lung metastasis * Bowel prep * Recurrent CRC * Any psychiatric disease * Emergency operations
References
Publications (4)
- RESULTFuchs P, Loeseken C, Schubert JK, Miekisch W. Breath gas aldehydes as biomarkers of lung cancer. Int J Cancer. 2010 Jun 1;126(11):2663-70. doi: 10.1002/ijc.24970. PMID 19839051
- RESULTBond A, Greenwood R, Lewis S, Corfe B, Sarkar S, O'Toole P, Rooney P, Burkitt M, Hold G, Probert C. Volatile organic compounds emitted from faeces as a biomarker for colorectal cancer. Aliment Pharmacol Ther. 2019 Apr;49(8):1005-1012. doi: 10.1111/apt.15140. Epub 2019 Mar 3. PMID 30828825
- RESULTArasaradnam RP, McFarlane MJ, Ryan-Fisher C, Westenbrink E, Hodges P, Thomas MG, Chambers S, O'Connell N, Bailey C, Harmston C, Nwokolo CU, Bardhan KD, Covington JA. Detection of colorectal cancer (CRC) by urinary volatile organic compound analysis. PLoS One. 2014 Sep 30;9(9):e108750. doi: 10.1371/journal.pone.0108750. eCollection 2014. PMID 25268885
- RESULTAltomare DF, Di Lena M, Porcelli F, Trizio L, Travaglio E, Tutino M, Dragonieri S, Memeo V, de Gennaro G. Exhaled volatile organic compounds identify patients with colorectal cancer. Br J Surg. 2013 Jan;100(1):144-50. doi: 10.1002/bjs.8942. PMID 23212621